Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA FY 1992 APPROPRIATIONS SET AT $ 759.9 MIL.

Executive Summary

FDA FY 1992 APPROPRIATIONS SET AT $ 759.9 MIL. under an agreement reached Oct. 3 by House and Senate negotiators on the Agriculture/FDA funding bill. Senate conferees ceded to the House bill's higher funding levels and other provisions in all areas except for the allotment for buildings and facilities. The House had proposed $ 10.3 mil. for buildings and facilities versus the Senate's $ 8.3 mil. ("The Pink Sheet" July 29, T&G-1). The added $ 2 mil. in the House bill was earmarked for planning for FDA's consolidated campus, but Senate negotiators pointed out that the FY 1992 Postal Service/General Government appropriations bill contains nearly $ 200 mil. for campus planning and construction (see related story below). The bill would provide $ 725.9 mil. for FDA salaries and general expenses; the Senate had proposed $ 704 mil... It also provides $ 25.6 mil. for rental payments. The $ 759.9 agency total is about $ 70 mil. more than FDA's FY 1991 appropriations. The conference bill must still be ratified by both House and Senate. A House floor vote is expected Oct. 8 or 9 and the Senate vote is expected shortly thereafter. The compromise retains the House's provision that would require FDA to submit a specific appropriations request for funds that would have come from user fees under the Bush Administration's budget plan. Absent the request, FDA would receive $ 537 mil. for salaries and expenses in 1992, $ 188.8 mil. less than the compromise funding level of $ 725.9 mil. Both the House and Senate Appropriations Committees have previously expressed strong objections to the Bush Administration's approach of including user fee revenues in its FDA budget plan before such fees are authorized in statute. The upcoming House-Senate conference report on Agriculture/FDA appropriations is expected to discuss this issue further. The conference agreement, however, struck provisions in the Senate bill that would have withheld $ 45.4 mil. of the allocation until FDA declares a funding "emergency" and another $ 51.5 mil. until the last day of the fiscal year. Those provisions to juggle FDA's accounts, as well as the Senate's lower proposed funding levels, arose because the Senate Appropriations Committee gave its Agriculture/FDA Subcommittee $ 500 mil. less to work with than did the House committee ("The Pink Sheet" Aug. 5, p. 5). However, Senate subcommittee members indicated early on that they wanted to increase FDA's budget in the House-Senate conference.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS019832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel